{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:51:16Z","timestamp":1785333076397,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00415-023-11925-6","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:02:21Z","timestamp":1692288141000},"page":"5819-5826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-3840","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Chanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bouhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Aub\u00e9-Nathier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martial","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Hacquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Petiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nadaj-Pakleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andoni","family":"Echaniz-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"11925_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"11925_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"11925_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2018.1525121","author":"L Fan","year":"2018","unstructured":"Fan L, Ma S, Yang Y et al (2018) Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurol Res. https:\/\/doi.org\/10.1080\/01616412.2018.1525121","journal-title":"Neurol Res"},{"key":"11925_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","volume":"230","author":"S Suzuki","year":"2011","unstructured":"Suzuki S, Utsugisawa K, Nagane Y et al (2011) Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230:148\u2013152. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.10.023","journal-title":"J Neuroimmunol"},{"key":"11925_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1212\/WNL.43.9.1779","volume":"43","author":"PB Christensen","year":"1993","unstructured":"Christensen PB, Jensen TS, Tsiropoulos I et al (1993) Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology 43:1779\u20131783","journal-title":"Neurology"},{"key":"11925_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2169\/internalmedicine.44.572","volume":"44","author":"M Matsuda","year":"2005","unstructured":"Matsuda M, Dohi-Iijima N, Nakamura A et al (2005) Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan. Intern Med Tokyo Jpn 44:572\u2013577","journal-title":"Intern Med Tokyo Jpn"},{"key":"11925_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A, Clover L, Buckley C et al (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74:1105\u20131108","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11925_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.regg.2018.10.004","volume":"54","author":"JM Aragon\u00e8s","year":"2019","unstructured":"Aragon\u00e8s JM, Altimiras J, Molist N et al (2019) Under-diagnosis of neuromuscular diseases in patients of 80 years and older. Rev Espanola Geriatr Gerontol 54:99\u2013102. https:\/\/doi.org\/10.1016\/j.regg.2018.10.004","journal-title":"Rev Espanola Geriatr Gerontol"},{"key":"11925_CR9","doi-asserted-by":"publisher","first-page":"e36603","DOI":"10.1371\/journal.pone.0036603","volume":"7","author":"AH Maniaol","year":"2012","unstructured":"Maniaol AH, Elsais A, Lorentzen \u00c5R et al (2012) Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS ONE 7:e36603. https:\/\/doi.org\/10.1371\/journal.pone.0036603","journal-title":"PLoS ONE"},{"key":"11925_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx A, Pfister F, Schalke B et al (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875\u2013884. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.007","journal-title":"Autoimmun Rev"},{"key":"11925_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/01.wnl.0000176067.32186.a3","volume":"65","author":"FE Somnier","year":"2005","unstructured":"Somnier FE (2005) Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65:928\u2013930. https:\/\/doi.org\/10.1212\/01.wnl.0000176067.32186.a3","journal-title":"Neurology"},{"key":"11925_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1405.040","volume":"1132","author":"JA Aarli","year":"2008","unstructured":"Aarli JA (2008) Myasthenia gravis in the elderly: Is it different? Ann N Y Acad Sci 1132:238\u2013243. https:\/\/doi.org\/10.1196\/annals.1405.040","journal-title":"Ann N Y Acad Sci"},{"key":"11925_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.nmd.2023.02.013","volume":"33","author":"Y-L Tang","year":"2023","unstructured":"Tang Y-L, Ruan Z, Su Y et al (2023) Clinical characteristics and prognosis of very late-onset myasthenia gravis in China. Neuromuscul Disord 33:358\u2013366. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.013","journal-title":"Neuromuscul Disord"},{"key":"11925_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.amjopharm.2007.10.001","volume":"5","author":"MW Bowie","year":"2007","unstructured":"Bowie MW, Slattum PW (2007) Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother 5:263\u2013303. https:\/\/doi.org\/10.1016\/j.amjopharm.2007.10.001","journal-title":"Am J Geriatr Pharmacother"},{"key":"11925_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/RMHP.S168750","volume":"12","author":"G Kojima","year":"2019","unstructured":"Kojima G, Liljas AEM, Iliffe S (2019) Frailty syndrome: implications and challenges for health care policy. Risk Manag Healthc Policy 12:23\u201330. https:\/\/doi.org\/10.2147\/RMHP.S168750","journal-title":"Risk Manag Healthc Policy"},{"key":"11925_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/CIA.S10252","volume":"6","author":"S Permpongkosol","year":"2011","unstructured":"Permpongkosol S (2011) Iatrogenic disease in the elderly: risk factors, consequences, and prevention. Clin Interv Aging 6:77\u201382. https:\/\/doi.org\/10.2147\/CIA.S10252","journal-title":"Clin Interv Aging"},{"key":"11925_CR17","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","volume":"48","author":"A Evoli","year":"2000","unstructured":"Evoli A, Batocchi AP, Minisci C et al (2000) Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 48:1442\u20131448","journal-title":"J Am Geriatr Soc"},{"key":"11925_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lpm.2006.07.003","volume":"36","author":"T Fraisse","year":"2007","unstructured":"Fraisse T, Labauge P, Camu W et al (2007) Myasthenia gravis in the elderly: diagnosis, comorbidity and course: 45 cases. Presse Medicale Paris Fr 1983 36:9\u201314. https:\/\/doi.org\/10.1016\/j.lpm.2006.07.003","journal-title":"Presse Medicale Paris Fr 1983"},{"key":"11925_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","volume":"325","author":"MA Hellmann","year":"2013","unstructured":"Hellmann MA, Mosberg-Galili R, Steiner I (2013) Myasthenia gravis in the elderly. J Neurol Sci 325:1\u20135. https:\/\/doi.org\/10.1016\/j.jns.2012.10.028","journal-title":"J Neurol Sci"},{"key":"11925_CR20","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94:e1171\u2013e1180. https:\/\/doi.org\/10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"key":"11925_CR21","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P et al (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263:1473\u20131494. https:\/\/doi.org\/10.1007\/s00415-016-8045-z","journal-title":"J Neurol"},{"key":"11925_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"11925_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s004150050585","volume":"247","author":"T Sharshar","year":"2000","unstructured":"Sharshar T, Chevret S, Mazighi M et al (2000) Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 247:286\u2013290","journal-title":"J Neurol"},{"key":"11925_CR24","volume-title":"Common terminology criteria for adverse events (CTCAE) v.50","author":"U.S. Department of Health and Human Services","year":"2017","unstructured":"U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE) v.50. U.S. Department of Health and Human Services"},{"key":"11925_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","volume":"130","author":"DB Sanders","year":"2019","unstructured":"Sanders DB, Arimura K, Cui L et al (2019) Guidelines for single fiber EMG. Clin Neurophysiol 130:1417\u20131439. https:\/\/doi.org\/10.1016\/j.clinph.2019.04.005","journal-title":"Clin Neurophysiol"},{"key":"11925_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13760-019-01252-x","volume":"120","author":"S Yildiz Celik","year":"2020","unstructured":"Yildiz Celik S, Durmus H, Yilmaz V et al (2020) Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurol Belg 120:133\u2013140. https:\/\/doi.org\/10.1007\/s13760-019-01252-x","journal-title":"Acta Neurol Belg"},{"key":"11925_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3988\/jcn.2012.8.3.161","volume":"8","author":"Z-F Mao","year":"2012","unstructured":"Mao Z-F, Mo X-A, Qin C et al (2012) Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol Seoul Korea 8:161\u2013169. https:\/\/doi.org\/10.3988\/jcn.2012.8.3.161","journal-title":"J Clin Neurol Seoul Korea"},{"key":"11925_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15:291\u2013298. https:\/\/doi.org\/10.1002\/ana.410150316","journal-title":"Ann Neurol"},{"key":"11925_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82:865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"11925_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","volume":"66","author":"V Fonseca","year":"1990","unstructured":"Fonseca V, Havard CW (1990) Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J 66:102\u2013105. https:\/\/doi.org\/10.1136\/pgmj.66.772.102","journal-title":"Postgrad Med J"},{"key":"11925_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.38.2.258","volume":"38","author":"R Hohlfeld","year":"1988","unstructured":"Hohlfeld R, Michels M, Heininger K et al (1988) Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38:258\u2013258. https:\/\/doi.org\/10.1212\/WNL.38.2.258","journal-title":"Neurology"},{"key":"11925_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/wnl.56.1.94","volume":"56","author":"V Chaudhry","year":"2001","unstructured":"Chaudhry V, Cornblath DR, Griffin JW et al (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56:94\u201396. https:\/\/doi.org\/10.1212\/wnl.56.1.94","journal-title":"Neurology"},{"key":"11925_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56:185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"11925_CR34","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","volume":"268","author":"I Lotan","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I (2021) Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol 268:4573\u20134586. https:\/\/doi.org\/10.1007\/s00415-020-10264-0","journal-title":"J Neurol"},{"key":"11925_CR35","doi-asserted-by":"publisher","first-page":"e2368","DOI":"10.1212\/WNL.0000000000200288","volume":"98","author":"A Molimard","year":"2022","unstructured":"Molimard A, Gitiaux C, Barnerias C et al (2022) Rituximab therapy in the treatment of juvenile myasthenia gravis: the french experience. Neurology 98:e2368\u2013e2376. https:\/\/doi.org\/10.1212\/WNL.0000000000200288","journal-title":"Neurology"},{"key":"11925_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2003","unstructured":"Mangoni AA, Jackson SHD (2003) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications: age-related changes in pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 57:6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x","journal-title":"Br J Clin Pharmacol"},{"key":"11925_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ensci.2016.02.004","volume":"2","author":"W Sakai","year":"2016","unstructured":"Sakai W, Matsui N, Ishida M et al (2016) Late-onset myasthenia gravis is predisposed to become generalized in the elderly. eNeurol Sci 2:17\u201320. https:\/\/doi.org\/10.1016\/j.ensci.2016.02.004","journal-title":"eNeurol Sci"},{"key":"11925_CR38","first-page":"129","volume":"153","author":"F Bill\u00e9-Turc","year":"1997","unstructured":"Bill\u00e9-Turc F, Padovani R, Pouget J et al (1997) Late onset myasthenia: 34 cases in patients over 65 years of age. Rev Neurol (Paris) 153:129\u2013134","journal-title":"Rev Neurol (Paris)"},{"key":"11925_CR39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.revmed.2005.08.009","volume":"26","author":"F Durand","year":"2005","unstructured":"Durand F, Camdessanch\u00e9 J-P, Jomir L et al (2005) Myasthenia in elderly patients: a series of 23 cases. Rev Med Internet 26:924\u2013930. https:\/\/doi.org\/10.1016\/j.revmed.2005.08.009","journal-title":"Rev Med Internet"},{"key":"11925_CR40","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"11925_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108.10.1212\/WNL.0000000000011108","author":"V Bril","year":"2020","unstructured":"Bril V, Benatar M, Andersen H et al (2020) Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: a phase 2 RCT. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000011108.10.1212\/WNL.0000000000011108","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11925-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11925-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T14:07:09Z","timestamp":1699452429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11925-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["11925"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11925-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JBC: non-financial support (hospitality) from LFB, Alexion and CSL-Behring; MM: non-financial support from Terumo, Novartis, Pfizer, LFB and personal fees from Pascaleo; PP: non-financial support from LFB; AEL: fees from Argenx and LFB; ACAN, AH, ANP, CV, FB and MS: nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study is in conformity with the World Medical Association Declaration of Helsinki 1964 and its later amendments. Patients previously gave their consent for the use of anonymized data. Ethical approval for the study was obtained from the institutional review board of the Strasbourg University Strasbourg, France (Number CE-2021-33). In view of the retrospective nature of the study and all the procedures being part of the routine care, no specific informed consent was required for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}